EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

CEST‐MRI for body oncologic imaging: are we there yet?

Elena Vinogradov iD, Jochen Keupp, Ivan E Dimitrov, Stephen Seiler, Ivan Pedrosa

NMR in Biomedicine · 2023-06 · 36 (6)

DOI: 10.1002/nbm.4906 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift NMR in Biomedicine, online erschienen am 15.02.2023. Verfasst von Elena Vinogradov und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Brain Neoplasms. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Cancer Prevention and Research Institute of Texas, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemical exchange saturation transfer (CEST) MRI has gained recognition as a valuable addition to the molecular imaging and quantitative biomarker arsenal, especially for characterization of brain tumors. There is also increasing interest in the use of CEST‐MRI for applications beyond the brain. However, its translation to body oncology applications lags behind those in neuro‐oncology. The slower migration of CEST‐MRI to non‐neurologic applications reflects the technical challenges inherent to imaging of the torso. In this review, we discuss the application of CEST‐MRI to oncologic conditions of the breast and torso (i.e., body imaging), emphasizing the challenges and potential solutions to address them. While data are still limited, reported studies suggest that CEST signal is associated with important histology markers such as tumor grade, receptor status, and proliferation index, some of which are often associated with prognosis and response to therapy. However, further technical development is still needed to make CEST a reliable clinical application for body imaging and establish its role as a predictive and prognostic biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Magnetic Resonance ImagingBrain NeoplasmsHumansBrainPrognosisMolecular Imaging

Stichwörter der Autor:innen

APTCESTMRIbody imagingoncologic imaging

Autor:innen und Institutionen

  • Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Philips Research, Hamburg, Germany.
  • Philips Healthcare, Gainesville, FL, USA.

ORCID-Profile: Elena Vinogradov

Förderung

  • NCI NIH HHS
  • Cancer Prevention and Research Institute of Texas
  • National Institutes of Health

Zitieren

APA

Vinogradov, E., Keupp, J., Dimitrov, I. E., Seiler, S., & Pedrosa, I. (2023). CEST‐MRI for body oncologic imaging: are we there yet?. NMR in Biomedicine, 36(6). https://doi.org/10.1002/nbm.4906

Vancouver

Vinogradov E, Keupp J, Dimitrov IE, Seiler S, Pedrosa I. CEST‐MRI for body oncologic imaging: are we there yet?. NMR in Biomedicine. 2023;36(6). doi:10.1002/nbm.4906

BibTeX
@article{Vinogradov2023,
  author = {Vinogradov, Elena and Keupp, Jochen and Dimitrov, Ivan E and Seiler, Stephen and Pedrosa, Ivan},
  title = {CEST‐MRI for body oncologic imaging: are we there yet?},
  journal = {NMR in Biomedicine},
  year = {2023},
  volume = {36},
  number = {6},
  doi = {10.1002/nbm.4906}
}
Kostenlos starten →